Equities Analysts Offer Predictions for AbbVie Q2 Earnings

AbbVie Inc. (NYSE:ABBV - Free Report) - William Blair issued their Q2 2025 EPS estimates for AbbVie in a note issued to investors on Wednesday, October 30th. William Blair analyst M. Phipps anticipates that the company will post earnings per share of $3.37 for the quarter. William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for AbbVie's current full-year earnings is $10.95 per share.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $3.00 earnings per share for the quarter, beating analysts' consensus estimates of $2.92 by $0.08. The firm had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.28 billion. AbbVie had a return on equity of 226.99% and a net margin of 9.22%. AbbVie's quarterly revenue was up 3.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.95 EPS.

Several other brokerages have also recently commented on ABBV. TD Cowen increased their price target on shares of AbbVie from $195.00 to $225.00 and gave the stock a "buy" rating in a research report on Monday, October 7th. UBS Group lifted their target price on AbbVie from $195.00 to $200.00 and gave the stock a "neutral" rating in a research report on Thursday. Citigroup raised their price objective on AbbVie from $215.00 to $226.00 and gave the stock a "buy" rating in a research note on Thursday. Barclays boosted their target price on shares of AbbVie from $200.00 to $212.00 and gave the company an "overweight" rating in a research note on Monday, October 7th. Finally, Truist Financial raised their price target on shares of AbbVie from $210.00 to $215.00 and gave the stock a "buy" rating in a research report on Thursday, October 10th. Four research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $201.00.

AbbVie Stock Down 1.5 %

ABBV stock traded down $3.08 during mid-day trading on Monday, hitting $200.47. 3,530,932 shares of the company were exchanged, compared to its average volume of 5,320,956. The firm has a fifty day simple moving average of $194.12 and a 200 day simple moving average of $179.60. The company has a market capitalization of $354.10 billion, a PE ratio of 70.08, a price-to-earnings-growth ratio of 2.78 and a beta of 0.63. AbbVie has a twelve month low of $135.85 and a twelve month high of $207.32. The company has a current ratio of 0.81, a quick ratio of 0.71 and a debt-to-equity ratio of 8.51.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ABBV. Vanguard Group Inc. boosted its stake in shares of AbbVie by 6.2% during the 1st quarter. Vanguard Group Inc. now owns 170,376,746 shares of the company's stock worth $31,025,605,000 after acquiring an additional 9,978,415 shares in the last quarter. International Assets Investment Management LLC boosted its position in shares of AbbVie by 1,745.0% in the 3rd quarter. International Assets Investment Management LLC now owns 4,728,063 shares of the company's stock valued at $933,698,000 after purchasing an additional 4,471,806 shares during the period. Capital World Investors raised its holdings in AbbVie by 249.1% during the 1st quarter. Capital World Investors now owns 4,373,184 shares of the company's stock worth $796,357,000 after buying an additional 3,120,310 shares during the period. Capital International Investors lifted its stake in AbbVie by 6.9% during the first quarter. Capital International Investors now owns 48,098,784 shares of the company's stock valued at $8,758,789,000 after buying an additional 3,110,601 shares in the last quarter. Finally, TD Asset Management Inc boosted its holdings in shares of AbbVie by 156.0% in the first quarter. TD Asset Management Inc now owns 3,474,020 shares of the company's stock worth $632,619,000 after buying an additional 2,116,997 shares during the period. Institutional investors own 70.23% of the company's stock.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Shareholders of record on Wednesday, January 15th will be given a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a yield of 3.27%. This is an increase from AbbVie's previous quarterly dividend of $1.55. The ex-dividend date of this dividend is Wednesday, January 15th. AbbVie's dividend payout ratio is 215.28%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.